Detalhe da pesquisa
1.
A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy.
Cell
; 178(1): 152-159.e11, 2019 06 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-31178121
2.
Preclinical safety and efficacy characterization of an LpxC inhibitor against Gram-negative pathogens.
Sci Transl Med
; 15(708): eadf5668, 2023 08 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37556556
3.
Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome.
Sci Immunol
; 5(54)2020 12 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33288645
4.
Human B Cell Clonal Expansion and Convergent Antibody Responses to SARS-CoV-2.
Cell Host Microbe
; 28(4): 516-525.e5, 2020 10 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32941787
5.
SARS-CoV-2 Antibody Responses Correlate with Resolution of RNAemia But Are Short-Lived in Patients with Mild Illness.
medRxiv
; 2020 Aug 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-32839786
6.
Human B cell clonal expansion and convergent antibody responses to SARS-CoV-2.
bioRxiv
; 2020 Jul 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32676593
7.
Curative Treatment of Severe Gram-Negative Bacterial Infections by a New Class of Antibiotics Targeting LpxC.
mBio
; 8(4)2017 07 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-28743813
8.
Drug design from the cryptic inhibitor envelope.
Nat Commun
; 7: 10638, 2016 Feb 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-26912110
9.
Structural basis of the promiscuous inhibitor susceptibility of Escherichia coli LpxC.
ACS Chem Biol
; 9(1): 237-46, 2014 Jan 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-24117400